Novo Nordisk appoints Eddie Li VP
This article was originally published in Scrip
Novo Nordisk has named Dr Eddie Li vice-president of regulatory affairs, effective 12 September 2011. Dr Li will be reporting to Dr Anne Phillips, corporate vice-president of clinical development, medical and regulatory affairs for North America. He most recently served as global head of regulatory affairs at Sanofi, and has also worked at Johnson & Johnson, AstraZeneca and the FDA.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.